Phosphoproteomics reveals MAPK inhibitors enhance MET- and EGFR-driven AKT signaling in KRAS-mutant lung cancer

Pathway inhibition of the RAS-driven MAPK pathway using small-molecule kinase inhibitors has been a key focus for treating cancers driven by oncogenic RAS, yet significant clinical responses are lacking. Feedback reactivation of ERK driven by drug-induced RAF activity has been suggested as one of th...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Mol Cancer Res
Autori principali: Kim, Jae-Young, Welsh, Eric A., Fang, Bin, Bai, Yun, Kinose, Fumi, Eschrich, Steven A., Koomen, John M., Haura, Eric B.
Natura: Artigo
Lingua:Inglês
Pubblicazione: 2016
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5065770/
https://ncbi.nlm.nih.gov/pubmed/27422710
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1541-7786.MCR-15-0506
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi